SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study

References

• OmuraMTorigoeSKubotaNSN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroidsRadiother Oncol1997431972019192967
   PubMed Web of Science ®Google Scholar
• Meyer-LosicFNicolazziCQuinoneroJDTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studiesClin Cancer Res2008142145215318381956
   PubMed Web of Science ®Google Scholar
• AbigergesDChabotGGArmandJPHéraitPGouyetteAGandiaDPhase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patientsJ Clin Oncol1995132102217799022
   PubMed Web of Science ®Google Scholar
• MiZBurkeTGDifferential interactions of camptothecin lactone and carboxylate forms with human blood componentsBiochemistry19943310325103368068669
   PubMed Web of Science ®Google Scholar
• HuangQWangLLuWEvolution in medicinal chemistry of E-ring-modified camptothecin analogs as anticancer agentsEur J Med Chem20136374675723578545
   PubMed Web of Science ®Google Scholar
• ThakurRSivakumarBSavvaMThermodynamic studies and loading of 7-ethyl-10-hydroxycamptothecin into mesoporous silica particles MCM-41 in strongly acidic solutionsJ Phys Chem B20101145903591120380409
   PubMed Web of Science ®Google Scholar
• ZuninoFPratesiGCamptothecins in clinical developmentExpert Opin Investig Drugs200413269284
   PubMed Web of Science ®Google Scholar
• SapraPZhaoHMehligMNovel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory modelClin Cancer Res2008141888896
   Google Scholar
• Garcia-CarboneroRSupkoJGCurrent perspectives on the clinical experience, pharmacology, and continued development of the camptothecinsClin Cancer Res2002864166111895891
   PubMed Web of Science ®Google Scholar
• BalaVRaoSBoydBJPrestidgeCAProdrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38J Control Release2013172486123928356
   PubMed Web of Science ®Google Scholar
• KurzrockRGoelSWhelerJSafety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignanciesCancer20121186144615122674635
   PubMed Web of Science ®Google Scholar
• KoizumiFKitagawaMNegishiTNovel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumorsCancer Res200666100481005617047068
   PubMed Web of Science ®Google Scholar
• HamaguchiTDoiTEguchi-NakajimaTPhase I study of NK012, a novel sn-38-incorporating micellar nanoparticle, in adult patients with solid tumorsClin Cancer Res2010165058506620943763
   PubMed Web of Science ®Google Scholar
• Alliance for Clinical Trials in OncologyLiposomal SN-38 in treating patients with metastatic colorectal cancer Available from: https://clinicaltrials.gov/ct2/show/NCT00311610. NLM identifier: NCT00311610Accessed March 13, 2018
   Google Scholar
• EbrahimnejadPDinarvandRJafariMRTabasiSAAtyabiFCharacterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38Int J Pharm201140612212721185365
   PubMed Web of Science ®Google Scholar
• WilliamsCCThangSHHantkeTRAFT-derived polymer–drug conjugates: poly(hydroxypropylmethacrylamide) (HPMA)-7-ethyl-10-hydroxycamptothecin (SN-38) conjugatesChemMedChem2012728129122144261
   PubMed Web of Science ®Google Scholar
• SayariEDinarvandMAminiMMUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 deliveryInt J Pharm201447330431524905777
   PubMed Web of Science ®Google Scholar
• VangaraKKLiuJLPalakurthiSHyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancerAnticancer Res2013332425243423749891
   PubMed Web of Science ®Google Scholar
• DuYZhangWHeRDual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effectsBioorg Med Chem2017253247325828465086
   PubMed Web of Science ®Google Scholar
• BaselTMBalivadaSShresthaBTA cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer modelSmall2012891392022238072
   PubMed Web of Science ®Google Scholar
• CardilloTMGovindanSVSharkeyRMSacituzumab govitecan (IMMU-132), an anti-trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancersBioconjug Chem20152691993125915780
   PubMed Web of Science ®Google Scholar
• YingTWenYDimitrovDSPrecision immunomedicineEmerg Microbes Infect20176e2528442753
   PubMed Web of Science ®Google Scholar
• SahotaSVahdatLTSacituzumab govitecan: an antibody-drug conjugateExpert Opin Biol Ther2017171027103128503956
   PubMed Web of Science ®Google Scholar
• AtyabiFFarkhondehfaiAEsmaeiliFDinarvandRPreparation of PEGylated nanoliposomal formulation containing SN-38: in vitro characterization and in vivo biodistribution in miceActa Pharm20095913314419564139
   PubMed Web of Science ®Google Scholar
• ZwickeGLMansooriGAJefferyCJUtilizing the folate receptor for active targeting of cancer nanotherapeuticsNano Reviews2012318496
   PubMedGoogle Scholar
• Charles River Laboratories [website on the Internet] Available from: http://www.criver.comAccessed March 13, 2018
   Google Scholar
• RogerELagarceFBenoitJPDevelopment and characterization of a novel lipid nanocapsule formulation of SN38 for oral administrationEur J Pharm Biopharm20117918118821303693
   PubMed Web of Science ®Google Scholar
• LinCHAl-SuwayehSAHungCFChenCCFangJYCamptothecin-loaded liposomes with α-melanocyte-stimulating hormone enhance cytotoxicity toward and cellular uptake by melanomas: an application of nanomedicine on natural productJ Tradit Complement Med2013310210924716164
   PubMedGoogle Scholar
• SantiDVSchneiderELAshleyGWMacromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low Cmax, and low glucuronide formationJ Med Chem2014572303231424494988
   PubMed Web of Science ®Google Scholar
• LiJWangXZangTA review on phospholipids and their main applications in drug delivery systemsAsian J Pharm Sci2015108198
   Web of Science ®Google Scholar
• VukovićLKhatibFADrakeSPStructure and dynamics of highly PEG-ylated sterically stabilized micelles in aqueous mediaJ Am Chem Soc2011133134811348821780810
   PubMed Web of Science ®Google Scholar
• FuYKaoWJDrug release kinetics and transport mechanism of non-degradable and degradable polymeric delivery systemExpert Opin Drug Deliv2010742944420331353
   PubMed Web of Science ®Google Scholar
• ModiSAndersonBDDetermination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis methodMol Pharm2013103076308923758289
   PubMed Web of Science ®Google Scholar
• LombardoDCalandraPBarrecaDMagazùSKiselevMASoft interaction in liposome nanocarriers for therapeutic drug deliveryNanomaterials (Basel)20166E12528335253
   PubMedGoogle Scholar
• ElbayoumiTATorchilinVPEnhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell linesEur J Pharm Sci20073215916817707615
   PubMed Web of Science ®Google Scholar
• KlymchenkoASKrederRFluorescent probes for lipid rafts: from model membranes to living cellsChem Biol2014219711324361047
   PubMedGoogle Scholar
• ZylberbergCMatosevicSPharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscapeDrug Deliv2016233319332927145899
   PubMed Web of Science ®Google Scholar
• PaliwalSRPaliwalRAgrawalGPVyasSPLiposomal nanomedicine for breast cancer therapyNanomedicine (Lond)201161085110021955078
   PubMed Web of Science ®Google Scholar
• GorenDHorowitzATTzemachDTarshishMZalipskySGabizonANuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pumpClin Cancer Res200061949195710815920
   PubMed Web of Science ®Google Scholar
• ChenHAhnRvan den BosscheJThompsonDHO’HalloranTVFolate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxideMol Cancer Ther200981955196319567824
   PubMed Web of Science ®Google Scholar
• PalAKhanSWangYFPreclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulationAnticancer Res20052533134115816556
   PubMed Web of Science ®Google Scholar
• NishikawaKAraiHInoueKScavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophagesJ Biol Chem1990265522652312318890
   PubMed Web of Science ®Google Scholar
• FunatoKYodaRKiwadaHContribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasmaBiochim Biophys Acta199211031982041543704
   PubMed Web of Science ®Google Scholar
• HarashimaHSakataKFunatoKKiwadaHEnhanced hepatic uptake of liposomes through complement activation depending on the size of liposomesPharm Res1994114024068008707
   PubMed Web of Science ®Google Scholar
• ImmordinoMLDosioFCattelLStealth liposomes: review of the basic science, rationale, and clinical applications, existing and potentialInt J Nanomedicine2006129731517717971
   PubMed Web of Science ®Google Scholar
• RichTAKirichenkoAVCamptothecin schedule and timing of administration with irradiationOncology2001153741
   PubMed Web of Science ®Google Scholar
• ArakiEIshikawaMIigoMKoideTItabashiMHoshiARelationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11Jpn J Cancer Res1993846977028340259
   PubMedGoogle Scholar